Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2018 | 03-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||
| Net Income | -137,499 | -2,597 | 0 |
| Depreciation Amortization | 450 | N/A | 0 |
| Accounts payable and accrued liabilities | 1,268 | N/A | N/A |
| Other Working Capital | 13,515 | 2,602 | 0 |
| Other Operating Activity | 116,224 | 0 | 0 |
| Operating Cash Flow | $-6,042 | $5 | $0 |
| Cash Flows From Investing Activities | |||
| PPE Investments | -2,634 | N/A | 0 |
| Investing Cash Flow | $-2,634 | $N/A | $0 |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 3,321 | N/A | N/A |
| Other Financing Activity | 149,282 | 0 | 0 |
| Financing Cash Flow | $152,603 | $N/A | $0 |
| End Cash Position | 143,927 | 5 | 0 |
| Net Cash Flow | $143,927 | $5 | $0 |
| Free Cash Flow | |||
| Operating Cash Flow | -6,042 | 5 | 0 |
| Capital Expenditure | -2,634 | N/A | N/A |
| Free Cash Flow | -8,676 | 5 | 0 |